CompanyCAMPNasdaqWatertown, MA

CAMP4 Therapeutics Corporation

CAMP4 develops antisense oligonucleotide (ASO) therapeutics that amplify mRNA expression for genetic diseases.

SEC EDGAR ClinicalTrials.gov camp4tx.com

8-KSep 28Latest SEC filing

Aug 13Latest story

August 2026

CAMP4 clears regulatory hurdles in Australia, Argentina for SYNGAP1 trial

Aug 13Quarterly updateCAMP4 Therapeutics Corporation

CAMP4 Therapeutics closes second tranche of private placement, raising $50.1 million

Aug 4FinancingCAMP4 Therapeutics Corporation

July 2026

CAMP4 gets Australian clearance to start CMP-002 trial in SYNGAP1 disorder

Jul 27FinancingCAMP4 Therapeutics Corporation